Arch Gynecol Obstet:那些接受隆乳术变性的患者后悔了吗?

2022-07-09 医路坦克 MedSci原创

许多跨性别者(变性人)在他们的一生中寻求外科女性化手术,本文回顾分析2007-2020年在埃森大学医院接受手术的所有横断面妇女的病历,使用部分乳房Q增大问卷和有关包膜痉挛症状和再手术的附加问题进行研究

许多从男性到女性的跨性别者(变性人)在他们的一生中寻求外科女性化手术,以改善他们的性别焦虑症和生活质量。女性化的一个重要部分是塑造自然的、女性化的乳房。然而,通常最初进行的跨性激素治疗(CSHT)通常会导致乳房发育不足,通常甚至不符合乳房大小,而且在治疗的前六个月后也不会改变。因此,许多跨性别女性寻求外科隆胸。尽管近年来性别确认手术(GAS)变得越来越普遍,但很少有研究涉及手术隆胸的并发症和满意度。尤其是考虑到跨性别女性通常年龄较大,BMI较高,并患有既往的疾病,分析任何外科手术的风险和好处是非常重要的。此外,还有与植入手术相关的特定风险,如包膜痉挛或乳房植入相关淋巴瘤(BIA-ALCL)。还应考虑到CSHT可能增加患乳腺癌的风险,以及植入硅胶植入物导致影像检查的有效性有限。

这项研究的目的是通过使用胸问卷的部分内容采访 2007 至 2020 年间在埃森大学医院接受隆胸的所有跨性别女性,问卷中补充了要求再次手术和高级包膜紧缩的问题。此外,还搜索了存档的患者记录中的合并症和手术并发症。另一个目的是调查更高级别的包膜痉挛的发生情况,并试图确定危险因素。

方法:回顾分析2007-2020年在埃森大学医院接受手术的所有横断面妇女的病历,使用部分乳房Q增大问卷和有关包膜痉挛症状和再手术的附加问题进行研究。

结果:159例患者中99例(62%)在术后中位时间4年后完成问卷调查。5%的隆胸手术因并发症导致再次手术。在这一人群中,包膜痉挛(Baker分级III-IV)的发生率为3%。大多数患者(75%)对结果的满意度得分很高(超过70分),并否认在日常生活中因植入物而受到限制。所有患者都报告说,由于隆胸,他们的生活质量有所改善。

图 1:丰胸-Q评分

表1:根据BREAM-Q计算的值

结论:目前的研究表明,大多数患者对隆胸的结果非常满意,所有患者都无一例外地表示,由于手术的结果,他们的生活质量有所改善。再加上手术的低并发症发生率,可以假定有一个良好的风险收益比。此外,关于包膜挛缩率低的问题,提出了进一步了解该并发症的病因并进一步降低其发生率的新方法。

文献来源:Schoffer AK,  Bittner AK,  Hess J,Complications and satisfaction in transwomen receiving breast augmentation: short- and long-term outcomes.Arch Gynecol Obstet 2022 06;305(6)

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2044216, encodeId=29dc204421665, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Feb 04 18:24:08 CST 2023, time=2023-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011454, encodeId=d05f201145475, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Jan 01 00:24:08 CST 2023, time=2023-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756596, encodeId=1f441e5659639, content=<a href='/topic/show?id=794f9842127' target=_blank style='color:#2F92EE;'>#隆乳术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98421, encryptionId=794f9842127, topicName=隆乳术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a90b37200469, createdName=fmq_28614565, createdTime=Thu Feb 16 08:24:08 CST 2023, time=2023-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463819, encodeId=5bf4146381916, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Fri Jul 08 15:24:08 CST 2022, time=2022-07-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2044216, encodeId=29dc204421665, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Feb 04 18:24:08 CST 2023, time=2023-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011454, encodeId=d05f201145475, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Jan 01 00:24:08 CST 2023, time=2023-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756596, encodeId=1f441e5659639, content=<a href='/topic/show?id=794f9842127' target=_blank style='color:#2F92EE;'>#隆乳术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98421, encryptionId=794f9842127, topicName=隆乳术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a90b37200469, createdName=fmq_28614565, createdTime=Thu Feb 16 08:24:08 CST 2023, time=2023-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463819, encodeId=5bf4146381916, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Fri Jul 08 15:24:08 CST 2022, time=2022-07-08, status=1, ipAttribution=)]
    2023-01-01 yhy100200
  3. [GetPortalCommentsPageByObjectIdResponse(id=2044216, encodeId=29dc204421665, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Feb 04 18:24:08 CST 2023, time=2023-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011454, encodeId=d05f201145475, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Jan 01 00:24:08 CST 2023, time=2023-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756596, encodeId=1f441e5659639, content=<a href='/topic/show?id=794f9842127' target=_blank style='color:#2F92EE;'>#隆乳术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98421, encryptionId=794f9842127, topicName=隆乳术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a90b37200469, createdName=fmq_28614565, createdTime=Thu Feb 16 08:24:08 CST 2023, time=2023-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463819, encodeId=5bf4146381916, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Fri Jul 08 15:24:08 CST 2022, time=2022-07-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2044216, encodeId=29dc204421665, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Feb 04 18:24:08 CST 2023, time=2023-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011454, encodeId=d05f201145475, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Sun Jan 01 00:24:08 CST 2023, time=2023-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756596, encodeId=1f441e5659639, content=<a href='/topic/show?id=794f9842127' target=_blank style='color:#2F92EE;'>#隆乳术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98421, encryptionId=794f9842127, topicName=隆乳术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a90b37200469, createdName=fmq_28614565, createdTime=Thu Feb 16 08:24:08 CST 2023, time=2023-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1463819, encodeId=5bf4146381916, content=<a href='/topic/show?id=7d27381288e' target=_blank style='color:#2F92EE;'>#变性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38128, encryptionId=7d27381288e, topicName=变性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f69f6545041, createdName=huangdf, createdTime=Fri Jul 08 15:24:08 CST 2022, time=2022-07-08, status=1, ipAttribution=)]
    2022-07-08 huangdf

相关资讯

Diabetologia:糖尿病患者全因死亡率和未来并发症的种族差异

与健康人相比,糖尿病患者的寿命缩短,直接归因于高血糖、过量NEFA和胰岛素抵抗导致的大血管(包括冠状动脉疾病、外周动脉疾病和中风)和微血管(神经病变、肾病和视网膜病变)并发症的发展。

Front Med :新型预测模型分析新发银屑病关节炎患者的相关并发症研究

银屑病是一种慢性皮肤病,在发达国家影响 2-3% 的普通人群。本前瞻性研究的目的是确定与疾病和患者相关的特征,这些特征可以预测新发 PsA 中更高的“即时”严重程度。

老年高血压的5大特点!常与多种疾病并存,并发症多......

随着我国老龄化社会进程的加快,超过一半的老年人患有高血压,在大于80岁的高龄老年人群中,高血压的患病率接近90%。高血压是罹患脑卒中、心肌梗死乃至造成心脑血管死亡的首要独立危险因素。

Ann Palliat Med:自体软骨和硅胶假体隆鼻的疗效和并发症发生率有多大差别?

鼻整形术是一种整形外科手术,可以使用各种假体材料来雕刻或抬高鼻子以美化其形状,本文全面分析和比较了使用自体软骨(AC)和硅胶材料进行隆鼻手术的疗效和并发症发生率。

Int J Urol:机器人辅助根治性膀胱切除术后并发症的预测因素

评价了机器人辅助根治性膀胱切除术后的并发症,并揭示了是否存在术后并发症的预测因素。

AJG: 大型肝脏腺瘤和肝脏腺瘤病的发病危险因素和并发症分析

肝细胞腺瘤指生长在肝脏上的肿瘤。医学角度认为腺瘤属于良性肿瘤,肝细胞肝癌、胆管细胞癌则属于恶性肿瘤。育龄期女性为好发人群。